Fintel reports that on March 20, 2025, Craig-Hallum initiated coverage of Veracyte (NasdaqGM:VCYT) with a Buy recommendation.
Analyst Price Forecast Suggests 45.44% Upside
As of March 19, 2025, the average one-year price target for Veracyte is $46.31/share. The forecasts range from a low of $29.29 to a high of $56.70. The average price target represents an increase of 45.44% from its latest reported closing price of $31.84 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Veracyte is 411MM, a decrease of 7.70%. The projected annual non-GAAP EPS is -0.42.
What is the Fund Sentiment?
There are 621 funds or institutions reporting positions in Veracyte. This is an increase of 48 owner(s) or 8.38% in the last quarter. Average portfolio weight of all funds dedicated to VCYT is 0.26%, an increase of 18.42%. Total shares owned by institutions decreased in the last three months by 0.52% to 104,789K shares. 
The put/call ratio of VCYT is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Artisan Partners Limited Partnership holds 6,599K shares representing 8.47% ownership of the company. In its prior filing, the firm reported owning 5,023K shares , representing an increase of 23.89%. The firm increased its portfolio allocation in VCYT by 54.73% over the last quarter.
ARK Investment Management holds 4,204K shares representing 5.39% ownership of the company. In its prior filing, the firm reported owning 4,921K shares , representing a decrease of 17.05%. The firm decreased its portfolio allocation in VCYT by 9.50% over the last quarter.
Wellington Management Group Llp holds 4,085K shares representing 5.24% ownership of the company. In its prior filing, the firm reported owning 4,233K shares , representing a decrease of 3.63%. The firm decreased its portfolio allocation in VCYT by 83.57% over the last quarter.
ArrowMark Colorado Holdings holds 3,080K shares representing 3.95% ownership of the company. In its prior filing, the firm reported owning 2,982K shares , representing an increase of 3.18%. The firm increased its portfolio allocation in VCYT by 26.15% over the last quarter.
ARKK - ARK Innovation ETF holds 2,900K shares representing 3.72% ownership of the company. In its prior filing, the firm reported owning 3,844K shares , representing a decrease of 32.58%. The firm increased its portfolio allocation in VCYT by 16.20% over the last quarter.
Veracyte Background Information
(This description is provided by the company.)
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
